Oricell Therapeutics closed a $110 million pre-IPO financing round co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners1
The Shanghai-based CAR-T therapy biotech plans to go public following this funding round1
Lead asset Ori-C101 is a GPC3-targeted autologous CAR-T therapy for hepatocellular carcinoma that completed a phase 1 study with 10 patients, with the highest dose level achieving an objective response1
Oricell aims to make Ori-C101 the first globally-approved CAR-T therapy for hepatocellular carcinoma1
The company is advancing next-generation programs including in vivo CAR-T therapies for solid tumors1
Oricell has raised over $110 million in this final funding round, with previous rounds including $125 million series B in 2022, $45 million B1 round in 2023, and $70 million series C1 announced four months prior1
Proceeds will fund global expansion, clinical development, and technological capability strengthening1
Sources:
1. https://www.fiercebiotech.com/biotech/chinas-oricell-raises-100m-carcinoma-car-t-plans-ahead-ipo-push